Vertex Pharmaceuticals has caught investors’ eyes, but its stock performance isn’t exactly a mic-drop moment. Despite massive ...

Medical experts emphasized the importance of considering different patient needs when deciding which treatments to employ for pain management at a May 29 Axios event. Axios' Maya Goldman and Erica ...

Vertex (VRTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Vertex Pharmaceuticals's VRTX short percent of float has risen 27.71% since its last report. The company recently reported ...

Vertex (VRTX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

CRISPR Therapeutics CRSP is currently the only company in the world to have secured approval for a CRISPR-based gene therapy ...

Short interest in Vertex Pharmaceuticals jumped 27.5% in May, hitting 4.82 million shares—just under 2% of the float. This ...

For investors still seeking companiies with attractive long-term prospects, let's consider two in the biotech industry: ...

SpyGlass Pharma announced today that it closed a $75 million Series D financing round to support its drug delivery platform.

Vertex and Eli Lilly are revolutionizing non-opioid pain management with NaV1.8 advancements. See why I'm bullish about LLY ...